drugset / Trial / NCT01759823
Bone Marrow Derived Stem Cell Transplantation in T2DM
Phase 2/3
Completed
30 enrolled
Post Graduate Institute of Medical Education and Research, Chandigarh
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to improve the blood glucose level in type 2 diabetic patients.
Timeline
- Start
- 2012-12
- Primary completion
- 2014-12
- Completion
- 2015-10
Outcome
Met primary endpoint
paper Six out of 7 (90%) patients achieved the primary end-point. PMID 28690682 ↗
Publications
- Background Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, Sharma RR, Saluja K, Dutta P, Walia R, Minz R, Bhadada S, Das S, Ramakrishnan S. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Stem Cells Dev. 2009 Dec;18(10):1407-16. doi: 10.1089/scd.2009.0164.
- Bhansali S, Dutta P, Yadav MK, Jain A, Mudaliar S, Hawkins M, Kurpad AV, Pahwa D, Yadav AK, Sharma RR, Jha V, Marwaha N, Bhansali S, Bhansali A. Autologous bone marrow-derived mononuclear cells transplantation in type 2 diabetes mellitus: effect on beta-cell function and insulin sensitivity. Diabetol Metab Syndr. 2017 Jul 4;9:50. doi: 10.1186/s13098-017-0248-7. eCollection 2017.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell transplantation | Cell therapy | — | Other |
| Subject | autologous bone marrow-derived mononuclear cells | Cell therapy | — | Other |